Comparative Pharmacology
Head-to-head clinical analysis: EXKIVITY versus LENVATINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXKIVITY versus LENVATINIB.
EXKIVITY vs LENVATINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
Lenvatinib is a kinase inhibitor that inhibits the receptor tyrosine kinases (RTKs) including VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), FGFR1, FGFR2, FGFR3, FGFR4, PDGFRα, KIT, and RET. It also inhibits the kinase activities of other RTKs involved in tumor angiogenesis and tumor growth.
150 mg orally once daily with or without food.
24 mg orally once daily for differentiated thyroid carcinoma; 8 mg twice daily or 12 mg once daily in combination with everolimus for renal cell carcinoma; 12 mg once daily in combination with pembrolizumab for advanced endometrial carcinoma.
None Documented
None Documented
Clinical Note
moderateLenvatinib + Digoxin
"Lenvatinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLenvatinib + Digitoxin
"Lenvatinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLenvatinib + Deslanoside
"Lenvatinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLenvatinib + Acetyldigitoxin
"Lenvatinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Approximately 28 hours (range 22-35 hours); supports once-daily dosing with steady-state achieved in ~5-7 days.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Fecal (approximately 64% of dose) and renal (approximately 25% of dose, with <2% as unchanged drug).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor